The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | ASH datasets that will impact clinical practice in 2026: the MajesTEC-3 trial in RRMM
Elias Mai, MD, University Hospital Heidelberg, Heidelberg, Germany,
comments on the significance of the Phase III MajesTEC-3 trial (NCT05083169) that found excellent results combining teclistamab and daratumumab in relapsed/refractory multiple myeloma (RRMM). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think this year we have indeed a very important abstract that will impact the clinical practice next year. It’s the late breaker on the MajesTEC-3 trial. This was a randomized Phase III trial comparing teclistamab plus daratumumab against the standard of care with either DPD or DVD. And as you know, teclistamab is a bispecific antibody directed against BCMA and CD3. And the results that we see here are just tremendous...
I think this year we have indeed a very important abstract that will impact the clinical practice next year. It’s the late breaker on the MajesTEC-3 trial. This was a randomized Phase III trial comparing teclistamab plus daratumumab against the standard of care with either DPD or DVD. And as you know, teclistamab is a bispecific antibody directed against BCMA and CD3. And the results that we see here are just tremendous. So we saw that the three-year PFS rate was far above 80% for patients in the experimental arm and that there was a significant overall survival benefit. And this was indeed true with a chemotherapy-free regimen. So it’s a completely immunotherapy-based approach and we saw very very high response rate so I think hopefully we will have an approval next year for this drug and this will change the life of thousands of patients with relapsed/refractory multiple myeloma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
